TL;DR
The current understanding of heterogeneity and evolution is synthesized and it is discussed how these insights can inform the development of evolution-aware diagnostic and therapeutic strategies.
High-resolution mapping of 52,384 cells uncovers hierarchical intra-tumor heterogeneity in HCC and TMEM176B is identified as the link between tumor malignancy hierarchy and immune remodeling.
Despite major advances in cancer genomics and immunotherapy, the field remains limited by experimental models that fail to faithfully recapitulate human tumor initiation, genetic context, and immune-tumor interactions. Traditional animal and immortalized cell models often lack predictive power for therapeutic response...
Patient-derived organoids (PDOs) are widely used platforms for cancer modeling and precision oncology because they preserve patient-specific genetic backgrounds, recapitulate aspects of native tissue architecture, and allow long-term expansion, repeated functional interrogation, and drug screening. Accordingly, multi-o...
Anaplastic thyroid carcinoma (ATC) is a highly lethal malignancy whose therapeutic resistance is driven by profound intra-tumor heterogeneity and a complex tumor microenvironment. This review synthesizes how single-cell and spatial transcriptomic technologies are transforming our understanding of ATC by systematically...
Intratumor heterogeneity (ITH), the coexistence of diverse subclones within a single tumor, may pose a major challenge to effective chemotherapy in breast cancer. This cellular diversity contributes to treatment failure, residual disease, and early relapse by enabling tumor adaptation and therapeutic resistance. Althou...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
